Rocket Pharmaceuticals 将来の成長

Future 基準チェック /26

Rocket Pharmaceuticals利益と収益がそれぞれ年間51.5%と51.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-35.4% 51.3%なると予測されています。

主要情報

51.5%

収益成長率

51.3%

EPS成長率

Biotechs 収益成長	26.8%
収益成長率	51.3%
将来の株主資本利益率	-35.4%
アナリストカバレッジ	Good
最終更新日	30 Dec 2024

今後の成長に関する最新情報

Recent updates

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

業績と収益の成長予測

NasdaqGM:RCKT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	477	-23	-86	17	5
12/31/2026	165	-205	-185	-117	10
12/31/2025	56	-238	-236	-168	14
12/31/2024	0	-267	-251	-214	12
9/30/2024	N/A	-258	-202	-192	N/A
6/30/2024	N/A	-253	-210	-197	N/A
3/31/2024	N/A	-249	-210	-194	N/A
12/31/2023	N/A	-246	-211	-195	N/A
9/30/2023	N/A	-253	-236	-222	N/A
6/30/2023	N/A	-249	-219	-208	N/A
3/31/2023	N/A	-237	-206	-196	N/A
12/31/2022	N/A	-222	-186	-178	N/A
9/30/2022	N/A	-199	-160	-153	N/A
6/30/2022	N/A	-192	-147	-137	N/A
3/31/2022	N/A	-172	-145	-136	N/A
12/31/2021	N/A	-169	-129	-121	N/A
9/30/2021	N/A	-186	-122	-103	N/A
6/30/2021	N/A	-165	-108	-93	N/A
3/31/2021	N/A	-155	-92	-77	N/A
12/31/2020	N/A	-140	-95	-75	N/A
9/30/2020	N/A	-99	-98	-81	N/A
6/30/2020	N/A	-89	-98	-75	N/A
3/31/2020	N/A	-82	-99	-71	N/A
12/31/2019	N/A	-77	-88	-65	N/A
9/30/2019	N/A	-85	-81	-66	N/A
6/30/2019	N/A	-82	-75	-67	N/A
3/31/2019	N/A	-79	-60	-58	N/A
12/31/2018	N/A	-75	-55	-54	N/A
9/30/2018	N/A	-54	-40	-39	N/A
6/30/2018	N/A	-44	N/A	-31	N/A
3/31/2018	N/A	-32	N/A	-24	N/A
12/31/2017	N/A	-20	N/A	-16	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-11	N/A	-9	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RCKT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RCKT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RCKT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RCKTの収益 ( 51.3% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: RCKTの収益 ( 51.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RCKT 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/05 02:10
終値	2025/01/03 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Rocket Pharmaceuticals, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。25

アナリスト	機関
Jason Zemansky	BofA Global Research
Gregory Harrison	BofA Global Research
Yun Zhong	BTIG

Rocket Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 57%, EPS upgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Consensus revenue estimates fall by 95%

Price target decreased to US$53.18

Recent updates

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $165 million.

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Consensus revenue estimates decrease by 57%, EPS upgraded

VP, Senior Controller notifies of intention to sell stock

Rocket Pharmaceuticals' Promising Path In Gene Therapy

No longer forecast to breakeven

New minor risk - Insider selling

CEO & Director recently sold US$605k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold US$88k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 95%

CEO & Director notifies of intention to sell stock

Insider recently sold US$68k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Now 23% undervalued

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Price target decreased to US$53.18

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Rocket Pharma: Poised For Growth In The Rare Disease Space

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Price target decreased to US$58.50

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

Price target decreased to US$63.56

Consensus forecasts updated

CEO & Director recently bought US$382k worth of stock